The **Psoriasis Area and Severity Index (PASI)** is currently the gold-standard for measuring the severity of plaque psoriasis.

The PASI is a numeric score that ranges from 0 to 72, with higher numbers indicating more severe disease. It's calculated by assessing the extent and severity of psoriatic lesions in four body regions: the head, upper extremities, trunk, and lower extremities. PASI online calculators are available.

A PASI score of 0–5 is considered none to mild psoriasis, 6–10 is moderate psoriasis, and 11 or above is severe psoriasis.

PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Where E = erythema, I = induration, S = scaling, A = area, h = head score, u = upper extremities, t = trunk score, and l = lower extremities score.

The **Physician Global Assessment (PGA)** is used to determine a single estimate of the patient's overall severity of disease at a given point in time.

Psoriatic lesions are graded for induration, erythema, and scaling based on scales of 0 to 4 that are then averaged over all lesions.

The sum of the three scales are added and then divided by three (I + E + S/3) to obtain a final PGA score as follows: 0 = cleared, except for residual discoloration; 1 = minimal – majority of lesions have individual scores for I + E + S/3 that average 1; 2 = mild – majority of lesions have individual scores that average 2; 3 = moderate – majority of lesions have individual scores that average 3; 4 = severe – majority of lesions have individual scores that average 4.

Score	Induration	Erythema	Scaling
0	No evidence	No evidence of erythema although hyperpigmentation may be present	No evidence of scaling
1	Minimal	Faint erythema	Minimal: occasional fine scale
2	Mild or slight	Light red coloration	Fine scale dominates
3	Elevated	Red coloration	Moderate: coarse scale predominates
4	Marked	Dark to deep red coloration	Marked: thick, non-tenacious scale dominates

References:

Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar. Appendix 5, Validity of Outcome Measures. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534046/

Manchanda, Y., De, A., Das, S., & Chakraborty, D. (2023). Disease Assessment in Psoriasis. Indian journal of dermatology, 68(3), 278–281. https://doi.org/10.4103/ijd.ijd_420_23